XTL Biopharmaceuticals Ltd. (XTLB) AI Stock Analysis
XTLB AI stock analysis summary
AI ResearchXTL Biopharmaceuticals Ltd. (XTLB) is an Israeli biopharmaceutical company developing therapeutics for autoimmune conditions such as systemic lupus erythematosus. Over the trailing twelve months, the company generated $968,000 in revenue with an EPS of -$0.36. As of March 31, 2026, XTLB held $144,000 in cash against total debt of $269,000, resulting in negative shareholders' equity of -$254,000.
- Market cap
- $4.8M
- Revenue (TTM)
- $968,000
- P/E
- —
- 1Y return
- -62.9% S&P 500 16.8%
- Avg. target
- $30.00 1430.6% vs last close
Bull case
- The mean price target for XTLB stands at $30.00, representing a 1430.6% premium over its last close of $1.96.
- Revenue expanded at a 5-year compound annual growth rate of 54.0% from FY2018 through FY2024.
- Company insiders maintain skin in the game by holding 21.4% of total outstanding shares.
Bear case
- The company faces capital constraints with negative shareholders' equity of -$254,000 and cash reserves of $144,000 as of March 31, 2026.
- Existing shareholders have experienced massive dilution, highlighted by a 5-year share count increase of 294313.0% as of FY2025.
- Cash burn remains elevated with free cash flow of -$1.7M in FY2024 alongside 0 EPS beats over the last 4 quarters.
What XTL Biopharmaceuticals does
Headquartered in Ramat Gan, Israel, XTL Biopharmaceuticals Ltd. is a biopharmaceutical company focused on acquiring and developing treatments for autoimmune disorders. The company's lead drug candidate is hCDR1, a Phase II-ready compound designed to treat systemic lupus erythematosus and Sjogren's syndrome. XTL advances the development and potential commercialization of hCDR1 through a strategic licensing agreement with Yeda Research and Development Company Limited. Originally founded in 1993 as Xenograft Technologies Ltd. before adopting its current name in July 1995, the organization operates with 4 employees as it seeks to address unmet medical needs across autoimmune disease indications.
Growth and profitability
XTL Biopharmaceuticals reported revenue of $451,000 in FY2024 alongside an operating margin of -481.6% and a net loss of -$1.0M, or -$0.20 per share. This followed FY2022 revenue of -$459,000 with net income of -$1.3M, and FY2021 revenue of $1.5M with net income of $435,000. For FY2024, research and development expenses were $98,000, up from $30,000 in FY2022. For the trailing twelve months ended March 31, 2025, revenue reached $968,000 with an operating margin of 0.0% and an EPS of -$0.36. Quarterly earnings growth for the latest quarter fell 76.0% year-over-year.
Balance sheet and cash flow
As of March 31, 2026, XTL Biopharmaceuticals held $144,000 in cash and short-term investments against total debt of $269,000, resulting in net debt of $125,000. Total assets stood at $166,000, while the current ratio was 0.40. The company reported negative shareholders' equity of -$254,000. Operating cash flow in FY2024 was -$1.6M and free cash flow was -$1.7M. Additionally, the company recorded a 5-year share count change of 294313.0% as of FY2025.
Valuation and performance
XTL Biopharmaceuticals trades at an enterprise value of $6.0M and a market capitalization of $4.8M. Its price-to-sales multiple is 5.8x and its EV/EBITDA is 16.9x, both above the median of its US-listed Healthcare peers, which stand at 4.1x and 12.0x, respectively. The company carries a price-to-book ratio of 1.9x. Over the past year, XTLB shares fell 62.9%, trailing the S&P 500 return of 16.8%. Over a 5-year horizon, the stock fell 87.5% compared to an 83.0% gain for the S&P 500.
What analysts expect
Wall Street coverage provides a mean price target of $30.00 for XTL Biopharmaceuticals, which compares to a last close of $1.96 on October 16, 2026, implying an upside of 1430.6%. In terms of earnings performance, the company recorded 0 EPS beats over the last 4 quarters. Furthermore, for the latest reported quarter ended March 31, 2025, XTLB experienced a quarterly earnings decline of 76.0% year-over-year.
Key risks and what to watch
- Liquidity is severely pressured with a current ratio of 0.40 and net debt of $125,000 as of March 31, 2026.
- The business used -$1.6M in operating cash flow in FY2024 against cash reserves of only $144,000.
- The stock price sits 28.9% below its 200-day moving average and has declined 87.5% over the past 5 years.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this XTLB AI stock analysis
This page is an AI-written research summary of XTL Biopharmaceuticals Ltd. (XTLB). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: XTLB income statement, XTLB balance sheet, XTLB key metrics, XTLB chart. See the XTLB stock overview for the latest quote and news.
XTLB AI stock analysis FAQ
What does XTL Biopharmaceuticals Ltd. do?
XTL Biopharmaceuticals is an Israel-based biopharmaceutical firm focused on developing autoimmune therapies, led by its Phase II-ready candidate hCDR1 for systemic lupus erythematosus and Sjogren's syndrome.
What is the financial position of XTLB?
As of March 31, 2026, the company held $144,000 in cash against $269,000 in total debt, leading to negative shareholders' equity of -$254,000 and a current ratio of 0.40.
Does XTL Biopharmaceuticals pay a dividend?
No, XTL Biopharmaceuticals does not pay a dividend.
What is the analyst price target for XTLB?
The mean price target is $30.00, which represents a 1430.6% increase relative to its last close of $1.96 on October 16, 2026.
How has XTLB stock performed relative to the S&P 500?
Over the past year, XTLB shares declined 62.9% while the S&P 500 gained 16.8%, and over 5 years the stock fell 87.5% against an 83.0% gain for the index.